徐丹,张晓娟,陈洁,杨敏,刘双信,劳海燕
XU Dan,ZHANG Xiaojuan,CHEN Jie,YANG Min,LIU Shuangxin,LAO Haiyan

• 1:广州医科大学附属第二医院
• 2:广东省人民医院/广东省医学科学院
• 3:广州市第一人民医院

摘要(Abstract)：

目的本文旨在探讨临床药师在华法林剂量调整中的作用。方法临床药师参与1例动静脉内瘘血栓形成患者的治疗工作,从遗传和非遗传因素分析导致华法林维持剂量差异的原因,建议临床医师对患者进行CYP2C9和VKORC1基因型的检测,并根据基因型检测结果调整华法林剂量。结果基因型检测结果提示患者需要较高剂量的华法林才能达到目标值,患者经治疗后病情好转,凝血指标达标后出院。结论华法林的抗凝疗效受很多因素影响,临床药师通过对华法林多个基因的多态性与患者病理生理情况相结合,提高患者用药的有效性和安全性。
OBJECTIVE To explore the role of clinical pharmacist in warfarin dosage adjustments. METHODS Through participating in the treatment for a case of Arteriovenous fistula thrombosis,clinical pharmacist analyzed the cause of the warfarin maintenance dose difference from the genetic and non-genetic factors,suggested clinicians to detect patients CYP2C9 and VKORC1 genotypes,adjusted warfarin dose according to the results of genotype. RESULTS Genotyping results suggested that the patient required higher doses of warfarin in order to achieve the target value. After treatment,the disease condition of the patient was relieved.The patient was discharged from the hospital after coagulation index standard. CONCLUSION The anticoagulation effect of warfarin was affected by many factors, clinical pharmacist combined the genetic polymorphisms of warfarin related genes with patients physiological and pathological situation. The participation of clinical pharmacist can improve drug efficacy and safety.

关键词(KeyWords)： 华法林;临床药师;病例分析
warfarin;clinical pharmacists;case analysis

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 徐丹,张晓娟,陈洁,杨敏,刘双信,劳海燕
XU Dan,ZHANG Xiaojuan,CHEN Jie,YANG Min,LIU Shuangxin,LAO Haiyan

参考文献(References)：

• [1]Miao L,Yang J,Huang C,et al.Contribution of age,body weight.and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin:proposal for a new dosing regimen in Chinese patients[J].Eur J Clin Pharmacol,2007,63(12):1135-1141.
• [2]王海燕,肾脏病学(第3版)[M].北京:人民卫生出版社,2009:951-952.
• [3]Yang L,Ge W,Yu F,et al.Impact of VKORCl gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis[J].Thromb Res,2010,125(4):e159-166.
• [4]杨剑,缪丽燕,黄晨蓉,等.细胞色素氧化酶P4502C9以及维生素K环氧化物还原酶复合体1基因多态性对华法林抗凝疗效的影响[J].中华心血管病杂志,2008,36(2):137-139.
• [5]Wei M,Ye F,Xie D,et al.A new algorithm to predict warfarin dose from polymorphisms of CYP4F2,CYP2C9 and VKORC1and clinical variables:derivation in Han Chinese patients with non valvular atrial fibrillation[J].Thromb Haemost,2012,107(6):1083-1091.
• [6]International Warfarin Pharmacogenetics Consortium.Estimation of the warfarin dose with clinical and pharmacogenetic data[J].N Engl J Med,2009,360(8):753-764.
• [7]Huang SW,Chen HS,Wang XQ,et al.Validation of VKORC1and CYP2C9 genotypes on interindividual warfarin maintenance dose:a prospective study in Chinese patients[J].Pharmacogenet Genomics,2009,19(3):226-234.
• [8]Epstein RS,Moyer TP,Aubert RE,et al.Warfarin genotyping reduces hospitalization rates results from the MM-WES(Med CoMayo Warfarin Effectiveness study)[J].J Am Coll Cardiol,2010,55(25):2804-2812.